**Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as Bcl-2 in benign epithelium and cancer of the prostate**

RAMESH UMMANNI1,5, ULRIKE LEHNIGK2, UWE ZIMMERMANN,4 CHRISTIAN WOENCKHAUS3, REINHARD WALThER1 and JÜRGEN GIEBEL2

Departments of 1Medical Biochemistry and Molecular Biology, 2Anatomy and Cell Biology, and 3Pathology, 4Clinic and Policlinic of Urology, Ernst Moriz Arndt University of Greifswald, D-17487 Greifswald; 5Hubertus Wald Tumorzentrum-UCCH Onkologisches Zentrum-Medizinische Klinik II, Universitätsklinikum Hamburg-Eppendorf, D-20251 Hamburg, Germany

Received August 6, 2009; Accepted October 12, 2009

**Abstract.** Activation of caspases is an essential prerequisite for induction of apoptosis. In many tumors caspases are down-regulated, while anti-apoptotic Bcl-2 is up-regulated. To elucidate their putative role in prostate cancer (PCA) we determined the expression of different caspases and Bcl-2 in benign prostate epithelium (BPE) and PCA. Paraffin-embedded prostate whole mounts were cut (4 µm) and investigated immunohistochemically using monoclonal antibodies against caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6, and Bcl-2. In BPE all caspases were localized to the cytoplasm of glandular cells. In PCA we found a statistically significant reduction in cleaved caspase-3 and -6 compared to the levels in BPE. The Bcl-2 protein was detected in the basal compartment of epithelial gland cells, but no immunostaining was noted in PCA. The decreased immunoreactivity of activated caspases probably indicates an alteration in post-translational cleavage that may play an important role during PCA progression.

**Introduction**

Prostate cancer (PCA) is the second most common cause of cancer-related mortality among males in developed countries (1). It is well known that tissue homeostasis in the normal prostate gland (as in most other organs) is maintained by the quantitative relationship between the rate of cell proliferation and the rate of apoptotic cell death (2,3). Thus, apoptosis comprises an important role in the development of the prostate and in the normal process of prostatic glandular self-renewal. Consistently, dysregulation of apoptosis represents an important mechanism of prostate carcinogenesis.

The most prominent executioners of apoptosis are represented by the family of caspases comprising initiator (caspase-1, -2, -4, -5, -8, -9 and -10) and effector caspases (caspase-3, -6 and -7) (4,5). Caspases are cysteine proteases and are synthesized as inactive proenzymes (6). On activation (cleavage), effector caspases can cleave a broad range of intracellular targets thus leading to apoptosis. Activation of caspases and initiation of different apoptotic pathways depend on the cell type (7). In a few cell types active caspase-8 activates executioners such as caspase-3, -6 and -7 in a mitochondrial-independent manner. In contrast, in other cell types apoptosis involves mitochondrial death signals mediated by the Bcl-2 family proteins. Here, active caspase-8 cleaves Bid into a tBid (truncated form of Bid) that translocates to the mitochondria, promoting the release of cytochrome c into the cytosol (8). This, in turn, leads to the formation of the apoptosome and subsequently to the activation of caspase-3. Caspase-1 (known as interleukin-β-converting enzyme) is also required for apoptosis (9), and caspase-9 activity is dependent on cytosolic factors (10). Cytochrome c release from mitochondria initiates activation of caspase-9 which subsequently activates caspase-3 as an important executioner of apoptosis (11,12). Caspase-6, an important effector caspase, can activate caspase-3 resulting in apoptosis. The Bcl-2 gene product is a potent inhibitor of apoptosis, since it stabilizes the mitochondrial membrane and blocks the release of cytochrome c. In turn, cytochrome c can bind to caspase-9 which triggers the activation of caspase-3 (13,14). Taken together, a variety of proteins, e.g., caspases and members of the Bcl-2 family, are involved in tissue homeostasis.

Although expression of caspase-1 and -3 was shown to be decreased in PCa compared to benign prostate epithelium (BPE) (15), there is limited information on the role of caspases in PCa. Therefore, in the present study we investigated the expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6, and Bcl-2 in PCa.

**Correspondence to:** Professor Jürgen Giebel, Department of Anatomy and Cell Biology, Ernst Moriz Arndt University, Friedrich Loeffler-Str. 23c, D-17489 Greifswald, Germany

E-mail: giebel@uni-greifswald.de

**Key words:** caspases, prostate carcinoma, benign prostate epithelium, immunohistochemistry, Bcl-2
Materials and methods

Prostate specimens. In this study, we investigated 20 primary prostate adenocarcinomas localized at the peripheral zone of the prostate from patients undergoing radical prostatectomy due to PCA at the Clinic and Polyclinic of Urology, University of Greifswald. No patient had received any therapy before surgery. Patient age ranged from 52 to 71 years (mean age, 61.65 years). Tissue samples and patient data were obtained and used after recommendations from the Ethics Committee of the University of Greifswald and in accordance with the Declaration of Helsinki. The entire prostate glands were fixed in 4% buffered formalin (72 h, 4°C) immediately after radical prostatectomy and subsequently embedded in paraffin. Whole mount prostate were cut at 4 μm and mounted on precoated glass slides (Superfrost, Menzel, Braunschweig). All sections included in this study contained BPE glands showing benign prostate hyperplasia (BPH) and PCs.

Histopathological evaluation. Histological diagnosis and Gleason grading (16,17) was performed by two experienced pathologists (C.W. and G.L.) on H&E-stained paraffin sections. Immunostaining for active and inactive caspases was carried out in parallel on consecutive sections.

Immunohistochemistry. Expression of apoptosis-associated proteins was determined using primary antibodies against caspase-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), uncleaved and cleaved caspase-3 and -6 (New England Biolabs, Frankfurt, Germany), caspase-9 (Acris Antibodies, Hiddenhausen, Germany), as well as Bcl-2 (Biosource, Nivelles, Belgium), employing the 4plus™ Universal Immunoperoxidase Detection System (Biocarta, Hamburg, Germany). After deparaffinising and rehydration, endogenous peroxidase activity was blocked (Peroxydazed 1, Biocarta), and sections were subjected to antigen-retrieval (10 mM citrate buffer, pH 6.0) in a microwave oven (700 W for 20 min). Slides were then allowed to cool in citrate buffer (20 min), washed in tap water (2 min), distilled water (2 min) and finally in PBS buffer (pH 7.3). Blocking with blocking reagent (5 min; Background Eraser; Biocarta) was followed by incubation with the respective antibody (overnight at 4°C). Slides were washed in PBS buffer (2x5 min), incubated with secondary antibody (10 min; Universal Link; Biocarta) and washed in buffer (2x5 min). Slides were incubated with streptavidin-HRP solution (10 min) and washed in PBS (2x5 min). Visualization was achieved by incubation with 0.1% diaminobenzidine (Sigma) in PBS/0.01% H2O2 (8 min). Slides were counterstained with hematoxylin, dehydrated and mounted in Neo-mount (Merck, Darmstadt, Germany). Routine pathological observation was carried out on H&E-stained sections.

Control reactions to demonstrate specific antibody binding were carried out by i) incubation of slides with PBS and omitting all steps, except DAB-chromogen reaction, ii) omitting the primary antibody and iii) competitive inhibition for cleaved caspase-3 and -6, as previously demonstrated (18). Images were captured using an Olympus BX 50 microscope equipped with an Olympus DP 10 digital camera.

Table I. Gleason score and tumour stage of the 20 PCA samples.

<table>
<thead>
<tr>
<th>No. of specimens</th>
<th>Gleason score</th>
<th>pT tumour stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3-4</td>
<td>5-6</td>
</tr>
<tr>
<td>4</td>
<td>9</td>
<td>7</td>
</tr>
</tbody>
</table>

Immunohistochemical staining for all caspases and Bcl-2 was scored by visual assessment of ten x40 fields as followed: (+) 0-30% of prostate glands or tumour tissue immunopositive, (++) 31-70% of prostate glands or tumour tissue immunopositive and (+++) >71% of prostate glands or tumour tissue immunopositive.

Statistical analysis. Differences between caspase expression in benign and cancer tissue were analysed by a two-tailed Student’s t-test. P<0.05 was regarded as significant.

Results

Histology and grading of tumours. All prostates were evaluated by H&E staining and revealed Gleason scores between 3 and 8 and pT stage from 2a to 3c (Table I). During the clinical follow-up after surgery (24 months) metastases were diagnosed in one patient.

Immunohistochemistry and statistical analysis. Immunohistochemistry for caspase-1 showed a weak (+) cytoplasmic staining in non-neoplastic tissue and in the tumour tissue of all samples investigated. For caspase-9, immunostaining was observed in the cytoplasm of some prostate basal cells as well as in some tumour cells of all samples (+) (Table II, figures not shown). Caspase-3 immunoreactivity was predominantly seen in the cytoplasm of basal cells of normal prostate glands (+++). In most of the apical cells no immunostaining was evident (Fig. 1a). In the prostate tumour tissue of all of the patients, >50% of tumour cells were caspase-3-positive (+++) (Figs. 1b and 4a). Otherwise cleaved caspase-3 was strongly expressed in apical cells of the non-neoplastic tissue (+++), whereas only a few tumour cells were immunopositive for the active caspase (+) (P<0.0001) (Figs. 1c and d, and 4b). Immunostaining for caspase-6 was found in all basal and apical cells of normal prostate glands and in all tumour cells (+++) (Figs. 2a and b, and 4c). Cleaved caspase-6 was strongly expressed (+++) in apical cells of the normal prostate glands, whereas the tumour cells showed moderate immunostaining (+++) (P<0.0001) (Figs. 2c and d, and 4d). Immunohistochemical expression of Bcl-2 was noted in nearly all basal cells of the non-neoplastic prostate glands (+++). Tumour tissue, however, showed a weak immune response for Bcl-2 (+) (P<0.0001) (Figs. 3a and b, and 4e). In the control sections no staining was evident.

Discussion

The human prostate is composed of three anatomical zones: the peripheral (PZ), central (CZ) and the transition (TZ) zone (19). The PZ comprises 70% of the prostate, and a majority of
Table II. Summary of patient data and expression of caspases in normal and tumour tissue.

<table>
<thead>
<tr>
<th>Specimen</th>
<th>A</th>
<th>Gl</th>
<th>G</th>
<th>pT</th>
<th>M</th>
<th>Caspase-3</th>
<th>Caspase-6</th>
<th>Caspase-1</th>
<th>Caspase-9</th>
<th>Bcl-2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Uncleaved</td>
<td>Cleaved</td>
<td>Uncleaved</td>
<td>Cleaved</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BPE</td>
<td>PCA</td>
<td>BPE</td>
<td>PCA</td>
<td>BPE</td>
</tr>
<tr>
<td>1</td>
<td>62</td>
<td>3+4=7</td>
<td>3a</td>
<td>2b</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>3+3=6</td>
<td>2a</td>
<td>2b</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>2+3=5</td>
<td>1b</td>
<td>2b</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>2+3=5</td>
<td>2a</td>
<td>3a</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>70</td>
<td>3+4=7</td>
<td>3a</td>
<td>2c</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>62</td>
<td>3+4=7</td>
<td>3a</td>
<td>2c</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>71</td>
<td>3+4=7</td>
<td>3a</td>
<td>3c</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>2+2=4</td>
<td>1b</td>
<td>2c</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>67</td>
<td>2+2=4</td>
<td>1b</td>
<td>2a</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>68</td>
<td>2+3=5</td>
<td>3a</td>
<td>2c</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>11</td>
<td>59</td>
<td>1+2=3</td>
<td>1b</td>
<td>2b</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>12</td>
<td>60</td>
<td>2+3=5</td>
<td>1b</td>
<td>2b</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>13</td>
<td>68</td>
<td>3+4=7</td>
<td>3a</td>
<td>2c</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>14</td>
<td>66</td>
<td>2+3=5</td>
<td>2b</td>
<td>2a</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>15</td>
<td>70</td>
<td>2+3=5</td>
<td>2b</td>
<td>2b</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>65</td>
<td>2+3=5</td>
<td>2b</td>
<td>2a</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>66</td>
<td>3+4=7</td>
<td>3a</td>
<td>3a</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>18</td>
<td>65</td>
<td>3+5=8</td>
<td>3a</td>
<td>2b</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>19</td>
<td>64</td>
<td>1+2=3</td>
<td>1b</td>
<td>2a</td>
<td>0</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>20</td>
<td>65</td>
<td>2+3=5</td>
<td>2a</td>
<td>2b</td>
<td>0</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

A, age at diagnosis (years); Gl, Gleason score; G, grading; pT, tumour stage; M, metastasis; BPE, benign prostate epithelium, PCA, prostate cancer. Immunohistochemical score: +, 1; ++, 2; ++++, 3. *Not investigated due to limited material.

Figure 1. Immunostaining of uncleaved and cleaved caspase-3 in BPE and PCA. Uncleaved caspase-3 in BPE (a) and in PCA (b); cleaved caspase-3 in BPE (c) and in PCA (d). Bar represents 100 µm.
tumours originate from this zone (20, 21). Most of the benign hyperplastic nodules called nodular hyperplasia, besides a few carcinomas, originate from the TZ (22). The CZ constitutes approximately 25% of the prostate and is less frequently affected by prostate diseases (22, 23). In the present study, we evaluated the immunohistochemical expression of caspases and Bcl-2 in the PZ of whole mount prostate sections. Here, we demonstrated a decreased immunostaining for active caspase-3 and -6, while expression of uncleaved caspase-3 and -6 appeared not to be altered in PCA compared to BPE. Previous immunohistochemical studies revealed somewhat contradictory results. For instance, immunohistochemistry showed the presence of caspase-3 (inactivated form) in basal as well as secretory cells of benign prostate hyperplasia (BPH). Moreover, increasing grades of PCa showed a significant loss of caspase-3 expression, and it was concluded that altered caspase-3 expression may represent an additional mechanism of apoptotic resistance to androgen ablation (24). On the other hand, it was shown that expression of caspase-3 did not correlate with the number of apoptotic bodies and Gleason score (25), while another study revealed that the expression of caspase-3 was reduced in poorly differentiated prostate tumours rather than well-differentiated PCa and BPE. Therefore, a prognostic significance has been suggested in disease progression (15). However, the findings of Ananthanarayanan et al demonstrating decreased expression of active caspase-3 in high grade prostate intraepithelial neoplasia (PIN) and PCa (26) is in line with our findings. As in our study, immunostaining for uncleaved caspase-3 was not altered, but cleaved caspase-3 staining was significantly lower in PCa compared to BPE.
decreased in PCA. This suggests an alteration of post-translational cleavage of caspase-3 into active caspase-3. Therefore, modifications of proteolytic cleavage of its precursor form could lead to lower levels of active caspase-3. Consistently, this could represent a mechanism of apoptosis suppression thus supporting cancer development. As increased caspase-3 expression has been correlated with increased apoptosis and high histologic grade in breast carcinomas (27), cancer progression appears not to be necessarily associated with the down-regulation of caspase-3.

According to our current understanding, caspase-6 is an effector caspase that is activated downstream of caspase-3 during apoptosis. Activation of procaspase-6 by caspase-3 results in an active enzyme capable of cleaving an artificially introduced lamin cleavage site. This suggests that caspase-3 is activated prior to caspase-6 and may be responsible for the activation of caspase-6 (28). However, these results are in conflict with a previous study showing that caspase-6 is capable of activating caspase-3 and that active caspase-6 initiates activation of caspase-3 as shown in rodent cerebellar granule cells (29). Therefore, we focused our attention towards the investigation of caspase-6 expression in PCA. Notably, immunohistochemistry revealed no alteration in the expression of caspase-6, but a significant reduction in immunoreactivity for cleaved caspase-6 in PCA compared to BPE as noted for cleaved caspase-3. In recent studies, the camptothesin resistant prostate cancer cell line DU145 showed decreased expression of procaspase-6 indicating an important role of caspase-6 in drug-induced apoptosis (30). Moreover, resveratrol-induced apoptotic signalling led to caspase-6-mediated cleavage of lamin A in colon carcinoma cells (31).

**Figure 4.** Mean caspase-3 (a) and cleaved caspase-3 (b) immunohistochemistry scores in normal/tumour samples. Differential expression of caspase-3 (a) in PCA was not significant (NS) compared to BPE, whereas cleaved caspase-3 expression (b) was significant (P≤0.0001) in PCA (mean ± SEM, 1.44±0.166) in comparison with adjacent BPE (mean ± SEM, 2.83±0.09). Mean caspase-6 (c) and cleaved caspase-6 (d) immunohistochemistry scores in normal/tumour samples. Differential expression of caspase-6 (c) in PCA compared to BPE was not significant (NS), whereas cleaved caspase-6 expression (d) was significant (P≤0.0001) in PCA (mean ± SEM, 1.16±0.09) in comparison with adjacent BPE (mean ± SEM, 2.00±0.16). Mean values of Bcl-2 protein expression (e) in BPE and PCA samples. A 1.45-fold decrease (P≤0.0001) in Bcl-2 expression was observed in PCA (mean ± SEM, 1.3±0.105) in comparison with the BPE (mean ± SEM, 2.75±0.099). UC, uncleaved; C, cleaved.
worth noting that the proenzyme form of caspase-1, but not its active form, was previously detected in prostate cancer cells by Western blot analysis (15).

Previous reports suggest overexpression of Bcl-2 in PCA (32,33) and high grade PIN (34). This is in contrast to the results of our study, as we detected a faint staining (compared to non-neoplastic tissue) for the Bcl-2 protein in PCs of all of the sections investigated. Notably, a recent study did not show any significant alteration of Bcl-2 expression in pre-malignant tumours (26). Overexpression of Bcl-2 is linked to the restricted or cytochrome c release from mitochondria which in turn activates caspase-9 to induce apoptosis in PCA.

In conclusion, to the best of our knowledge, this is the first study to report expression of active and inactive caspases showing that caspases are expressed constitutively in neoplastic and non-neoplastic prostate cells. We suggest that activation of procaspases into active caspases could be disregulated in cancer tissue which in turn alters apoptosis. Further investigations to elucidate altered pathways for caspase activation must be pursued in order to discover novel strategies for the treatment of cancer.

Acknowledgements

The authors thank Professor Gerhard Lorenz (Department of Pathology, Ernst Moritz Arndt University of Greifswald) for the pathological classification of prostate sections. Ramesh Ummannì was supported by the Alfred-Krupp von Bohlen und Halbach Stiftung, Graduiertenkolleg Tumorbiologie and NGFN-Plus/NGFN-Transfer, Germany.

References